NCT07727694Recruiting
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
It involves collecting safety and efficacy data, under the actual conditions of use of off label and compassionate use medicines in children and adolescents approved in humans before 2007, using a validated tool (Ennov EDC) and relying on the network recognised pediatric hemato-oncology centers in Belgium and responsible for the organization of Pediatric National tumor boards which discuss each case of relapse in order to define the best therapeutic options.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1600 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- Jul 2026
- Primary completion date
- Dec 2030
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Childhood cancers
- NCT number
- NCT07727694
What you commit to
- Study type: Observational
- Planned participants: 1600
- From Jul 2026 to the primary completion date, Dec 2030
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient receiving the drug within a clinical trial.
Other
- Oral refusal to participate to the study, by the patient or his/her parents/legal representatives.
Who the study is looking for
- Age ≤ 25 at the time of inclusion in the study
- Patient with a pediatric malignancy (solid tumor or leukemia), or other related condition
- Patient not currently enrolled on any other trial for ongoing therapeutic purposes
- Patient treated with compassionate use of experimental drugs or off-label administration use of anti-cancer medicines first approved in adults after 2007 in Europe
- Patient discussed in a Pediatric multidisciplinary tumor boards (MDTB) to validate the inclusion in the SACHA study
- Consent to participate by the patient or his/her legal representatives in the study if required by ta particular national jurisdiction
Age in the registry: 0 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital, Antwerp Coordinator of this site? Confirm its status | Antwerp | Belgium | Not yet recruiting |
| Hôpital Universitaire des Enfants Reine Fabiola (Huderf) Coordinator of this site? Confirm its status | Brussels | Belgium | Not yet recruiting |
| Cliniques universitaires Saint-Luc Coordinator of this site? Confirm its status | Brussels | Belgium | Not yet recruiting |
| University Hospital Gent Coordinator of this site? Confirm its status | Ghent | Belgium | Not yet recruiting |
| University Hospital Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| CHC MontLégia Coordinator of this site? Confirm its status | Liège | Belgium | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.